Please assess the completion status of the following clinical trial:

Trial Title: Dose-Ranging Study to Assess the Safety, PK and Initial Antiviral Efficacy of NVR 3-778 in Chronic HBV Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Patients may be male or female between 18 and 65 years of age, with a BMI of 18-35kg/m2. Patients must be HBeAg positive and have chronic hepatitis B with no history of clinical decompensation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- NVR 3-778 (Type: EXPERIMENTAL): NVR 3-778 in varying doses of capsules by mouth for 28 days
- Placebo for NVR 3-778 (Type: PLACEBO_COMPARATOR): Placebo for NVR 3-778 in varying doses of capsules by mouth for 28 days
- NVR 3-778 and Pegasys (Type: EXPERIMENTAL): NVR 3-778 and Pegasys in combination in a yet to be determined dose by mouth and subcutaneous injection for 28 days
- Pegasys (Type: ACTIVE_COMPARATOR): Pegasys alone in a yet to be determined dose by subcutaneous injection for 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).